Latest News

MS Voice Newsletter – December 2022

December 21, 2022 | Advocacy, Awards, Education, Event, Life with MS, MS Voice, Newsletter

In our December edition of MS Voice we look back over an eventful year, celebrate the recipients of the Esme Tombleson Award, discuss MS symptoms and marvel at our wonderful findraisers. We also tell you how you can buy gifts […]


Esme Tombleson Award recipients 2022

December 21, 2022 | Advocacy, Awards

Multiple Sclerosis New Zealand is pleased to award Ingrid Robertson and Joan Perry with Esme Tombleson Awards for 2022, in recognition of their outstanding contributions to people impacted by Multiple Sclerosis nationally. Cantabrian Ingrid Robertson was diagnosed with MS in […]


MSNZ 2022 – A year in review

December 20, 2022 | Advocacy, My Story, Newsletter, Support

As we wind down for the holidays, at Multiple Sclerosis NZ, we have taken a moment to review what a year 2022 has been and celebrate our achievements. We continue to strive for our vision of ‘A world without MS’, […]


Update: Siponimod (Mayzent) for Secondary Progressive MS

November 16, 2022 | Advocacy, Funding, Treatments

At the August 2022 meeting of PHARMAC’s Pharmacology and Therapeutics Advisory Committee (PTAC), Multiple Sclerosis NZ (MSNZ) made a submission in support of the funding of Siponimod (Mayzent) for Secondary Progressive MS. At this meeting PTAC recommended listing with low priority and have requested further advice from the […]


Important notice for MS patients regarding Evusheld

November 16, 2022 | Advocacy, Covid-19, Treatments

Important notice for MS patients regarding EvusheldTM. EvusheldTM is a pre-exposure prophylaxis, which has shown positive results for reducing the impacts of COVID-19 on those who may lowered immunity against COVID 19 due to their MS treatments. Evusheld is NOT […]